| Title |
Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma
|
|---|---|
| Published in |
Molecular Cancer, December 2013
|
| DOI | 10.1186/1476-4598-12-153 |
| Pubmed ID | |
| Authors |
Long Chen, Shuang Zhou, Jie Qin, Heng Hu, Huiying Ma, Binbin Liu, Xuan Wang, Jiaqi Ma, Shenglong Ye, Cuiping Zhong, Guomin Zhou, Chunmin Liang |
| Abstract |
Secondary lymphoid tissue chemokine (SLC) is a key CC chemokine for chemotaxis of immune cells and has been an attractive candidate for anti-tumor treatments. However, among the immune cells recruited by SLC to tumors, the CD25+ Foxp3+ regulatory T cells (Tregs) compromise the anti-tumor effects. In this study, we proposed the combination therapy of intratumoral co-administration of SLC and anti-CD25 monoclonal antibodies (mAbs). We hypothesized that the intratumoral injections of SLC and depletion of Tregs would have stronger inhibition effects on the progression of hepatocellular carcinoma (HCC) in mice. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 5% |
| Unknown | 18 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 32% |
| Student > Ph. D. Student | 3 | 16% |
| Student > Master | 3 | 16% |
| Student > Bachelor | 2 | 11% |
| Student > Doctoral Student | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 4 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 42% |
| Agricultural and Biological Sciences | 3 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Sports and Recreations | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 4 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2013.
All research outputs
#14,767,396
of 22,733,113 outputs
Outputs from Molecular Cancer
#974
of 1,716 outputs
Outputs of similar age
#185,564
of 306,767 outputs
Outputs of similar age from Molecular Cancer
#25
of 49 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,716 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,767 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.